Innovent Biologics Inc

01801: XHKG (HKG)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|&gLOCK|fl?DLOCK|r^M!X$H

Innovent: Third-Quarter Revenue Update Reaffirms 2030 Targets; Shares Undervalued

Innovent's third-quarter 2026 revenue grew over 40% year-on-year, exceeding CNY 4.7 billion, driven by mazdutide, its GLP-1 drug, and recent proprietary products such as SINTBILO and SYCUME, two innovative injections.

Sponsor Center